Outlook Therapeutics Newsroom

BTIG Maintains Outlook Therapeutics(OTLK.US) With Buy Rating, Maintains Target Price $50

Futu NewsOct 19 00:31

BTIG Reiterates Buy on Outlook Therapeutics, Maintains $50 Price Target

BenzingaOct 18 23:27

Outlook Therapeutics Analyst Ratings

BenzingaOct 18 23:25

Capital One Financial Maintains Outlook Therapeutics(OTLK.US) With Buy Rating, Maintains Target Price $25

Futu NewsSep 4 22:31

Buy Rating Affirmed for Outlook Therapeutics Amid Strong Market Potential and Upcoming Milestones for ONS-5010/Lytenava

TipRanksSep 4 22:27

Outlook Therapeutics Price Target Maintained With a $53.00/Share by Chardan Capital

Dow JonesAug 17 00:54

Outlook Therapeutics Analyst Ratings

BenzingaAug 15 19:52

BTIG Maintains Outlook Therapeutics(OTLK.US) With Buy Rating, Maintains Target Price $50

Futu NewsAug 15 18:34

H.C. Wainwright Maintains Outlook Therapeutics(OTLK.US) With Buy Rating, Maintains Target Price $30

Futu NewsAug 15 18:31

Analysts Offer Insights on Healthcare Companies: Outlook Therapeutics (OTLK), Arrowhead Pharmaceuticals (ARWR) and Syndax Pharmaceuticals (SNDX)

TipRanksAug 15 18:06

Capital One Financial Maintains Outlook Therapeutics(OTLK.US) With Buy Rating, Maintains Target Price $25

Futu NewsAug 15 04:31

Buy Rating Justified by Outlook Therapeutics' Advancements and Market Prospects

TipRanksMay 29 08:06

HC Wainwright & Co. : The Outlook Therapeutics (OTLK.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $30.00.

Zhitong FinanceMay 17 22:31

Buy Rating Affirmed for Outlook Therapeutics on Strong EU Prospects and Solid Financial Position

TipRanksMay 17 18:21

Outlook Therapeutics Analyst Ratings

BenzingaMar 27 19:20

BTIG Upgrades Outlook Therapeutics to Buy, Announces $50 Price Target

BenzingaMar 27 19:20

Buy Rating for Outlook Therapeutics: Promising FDA Developments and Strong Financial Position Support $50 Price Target

TipRanksMar 27 18:51

Outlook Therapeutics: Buy Rating Affirmed Amid Positive European Developments and Anticipated U.S. Market Success

TipRanksMar 25 20:40

Outlook Therapeutics Analyst Ratings

BenzingaMar 25 20:35

Buy Rating Affirmed for Outlook Therapeutics: European Endorsement and Pivotal US Study Progress Signal Strong Market Potential

TipRanksMar 25 10:50